To the Gulf
A Turkish manufacturing or regulatory base can support entry into Gulf markets, where localisation is similarly prized — letting one investment serve two corridors.
Pairs with: Saudi ArabiaTurkey is a large, young, ambitious market that sits between Europe, the Gulf and Central Asia. It is also the corridor with the sharpest single idea: the state's pricing and reimbursement machinery consistently rewards local production. You can export into Turkey — but the fuller access, the reimbursed volume, tends to follow those who make something there.
Turkey regulates medicines and devices through TITCK, which controls licensing, GMP, pharmacovigilance, pricing and reimbursement. A foreign company cannot sell directly: you need a local presence, and every device must be entered in the UTS product-tracking system — no UTS record, no sale and no public tender. The defining feature is localisation. Turkey's older "localise or lose reimbursement" rule was challenged by the EU at the WTO (which the EU won in 2022) and the reimbursement regulation was revised — but through pricing, reference rules and national industrial strategy, local production still carries a real access advantage. Add a Euro-referenced price capped by a managed exchange rate, and the lira reality decides whether export-only economics work at all.
Most corridors ask who holds your registration. Turkey asks a blunter question: where do you make the product?
Turkey is genuinely attractive. It has more than 85 million people, a young population, a growing private healthcare sector, and geography that lets a Turkish base serve European, Gulf and Central Asian markets. Domestic manufacturing already covers a large share of local pharmaceutical demand, and the government has spent a decade steering the sector toward more local production, R&D and biotech through successive national strategies.
That industrial ambition is the context for everything commercial. The Turkish state is the dominant payer, and its pricing and reimbursement tools have repeatedly favoured products made in Turkey. For a German exporter, the message is uncomfortable but clear: you can enter on an export basis, but the economics and the access both improve markedly the moment you localise part of the value chain.
In Turkey, the registration lets you sell. The factory decides how much.
Almost every Turkey strategy resolves to one of these two shapes. The difference is not registration — both are registered — it is how much of the market each can actually reach.
Before the localisation question, there is a baseline you cannot skip — and it starts with someone Turkish standing in for you.
| Requirement | What it means | Why it bites |
|---|---|---|
| Local presence | A foreign company cannot register or sell directly; you work through a Turkish entity, affiliate or authorised local representative. | Your market access is mediated by whoever holds that role — the familiar corridor trap. |
| TITCK registration | The Turkish Medicines and Medical Devices Agency licenses medicines and devices and runs GMP, pharmacovigilance, pricing and reimbursement. | One agency controls both approval and whether you get paid. |
| UTS record (Urun Takip Sistemi) | Every device must be entered in the national product-tracking system. Non-EU makers also need a CE mark and an EU Authorised Representative. | No UTS record means the device cannot be sold, used, or entered in a public tender — full stop. |
| Reimbursement listing | Separate from the licence: getting onto the state reimbursement list under its pricing rules. | This is where localisation and reference pricing decide the real outcome. |
The UTS step is quick and free once the file is complete — but it is an absolute gate, exactly like the registration gates we describe on other corridors. Getting listed for reimbursement is the hard part, and it is where the next two sections live.
This is a live and contested area, so it is worth being precise rather than dramatic about it.
For years Turkey operated an explicit rule: foreign producers of certain medicines had to commit to manufacturing locally, or their products would lose reimbursement eligibility. The European Union challenged this at the WTO as discriminatory. In 2022 the arbitrators found against Turkey, and Turkey revised its drug reimbursement regulation. So the hard, written "localise or lose reimbursement" mandate in its original form is no longer the clean legal rule it once was.
What has not gone away is the direction of travel. Through pricing decisions, reference rules, tender preferences and an openly stated national strategy to raise local production and R&D, Turkey continues to make locally made products more competitive on reimbursement than pure imports. The lever changed shape; the incentive did not.
Do not plan as if there is a single rule that flips your product on or off. Plan as if local production sits on a gradient: the more of your value chain is in Turkey — from full manufacturing to fill-finish to a licensing or contract-manufacturing partner — the stronger your reimbursement and pricing position tends to be.
The parallel is Saudi Arabia, where localisation is pursued through procurement and Vision 2030 rather than a single statute. We map that version in the Saudi Arabia corridor.
Even before localisation, Turkish drug pricing has a structural feature that can quietly break an export model: the price is set in euros, then converted at a rate the state controls.
Turkey prices reimbursed medicines against an external reference basket and converts that euro price into lira using an official exchange rate that has historically been held well below the market rate. When the lira weakens faster than the state adjusts that conversion rate, the real lira price you receive erodes — while your costs, if you import, stay hard-currency. For an export-only model, this is the margin risk that matters most, and it compounds the localisation disadvantage.
Register in Turkey and you can be listed, reimbursed and still losing margin every time the lira moves — unless part of your cost base is also in lira.
The case for accepting Turkey's demands gets stronger when you stop seeing it as one country.
A Turkish manufacturing or regulatory base can support entry into Gulf markets, where localisation is similarly prized — letting one investment serve two corridors.
Pairs with: Saudi ArabiaTurkey's trade and cultural ties across Central Asia and its neighbourhood make a Turkish platform a springboard, not a cul-de-sac.
Pairs with: regional expansionSeen this way, localising in Turkey is not only the price of Turkish reimbursement — it can be the anchor of a wider regional footprint. Whether that logic beats simply going deeper in China or Southeast Asia is exactly the trade-off in our emerging-market decision guide.
Start with a fixed, written deliverable for the Turkey corridor, then plan execution in a working session — above all the export-versus-localise decision, which shapes everything downstream.
A one-off written roadmap for Turkey — the registration route, the UTS and local-presence requirements, and an honest read on the localisation and FX exposure.
A focused session to weigh export-only against local production, structure a local partner or fill-finish route, and use Turkey as a bridge.